465
Views
6
CrossRef citations to date
0
Altmetric
Letter to the Editor

The quest for effective Ebola treatment: Ebola VP35 is an evidence-based target for dsRNA drugs

&
Pages 1-2 | Received 18 Sep 2014, Accepted 22 Sep 2014, Published online: 25 Jan 2019

  • Goodman JL.Studying “Secrete Serums”—toward safe, effective Ebola treatments. N Engl J Med2014;371: 1086–1089.
  • Qiu X, Wong G, Audet J et al.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature2014;514: 47–53.
  • Gire SK, Goba A, Andersen KG et al.Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science2014;345: 1369–1372.
  • Feldman H, Sanchez A, Geisbert TW.Filoviridae: Marburg and Ebola viruses.In: Knipe DMand HowleyPM (eds.). Fields virology.6 ed.Philadelphia, PA: Lippincott Williams & Wilkins, 2013: 923–956.
  • Zinzula L, Tramontano E.Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Antiviral Res2013;100: 615–635.
  • Zinzula L, Esposito F, Pala D et al.dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35. Antiviral Res2012;93: 354–363.
  • Leung DW, Prins KC, Borek DM et al.Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol2010;17: 165–172.
  • Mitchell WM, Nicodemus CF, Carter WA et al.Discordant biological and toxicological species responses to TLR3 activation. Am J Pathol2014;184: 1062–1072.
  • Trumpfheller C, Longhi MP, Caskey M et al.Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med2012;271: 183–192.
  • Ichinohe T, Tamura S, Kawaguchi A et al.Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis2007;196: 1313–1320.